The place of metoprolol tartrate in the treatment of cardiovascular diseases

Abstract

Since the beginning of the 1960s, beta-blockers have been number one medications in the treatment of cardiovascular diseases. A number of randomized controlled trials (RCTs) demonstrated positive effect of beta-blockers on morbidity and mortality [1]. It is difficult to overestimate the role of beta-blockers in modern cardiology. According to the results of a meta-analysis of 18 RCTs, administration of beta-blockers in patients with a risk of cardiovascular disease was associated with a reduction of the risk of stroke by 29%, coronary heart disease (CHD) by 7%, and chronic heart failure (CHF) by 29% [2]. In combination with ACE inhibitors, antiplatelet agents and statins, beta blockers helped to decrease mortality from acute coronary syndrome by 90% [3].

Keywords

• сердечно-сосудистые заболевания
• бета-адреноблокаторы
• метопролола тартрат
• cardiovascular diseases
• beta-blockers
• metoprolol tartrate